Gastrointestinal Clinical Trials

Trial MenuList of Available Trials:

 

CINJOG 070806: “Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX‑Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG).”

ELIGIBILITY:

  • Histologically/cytologically proven colorectal carcinoma.

  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan.

  • Estimated life expectancy of at least 12 weeks.

  • Patients may have a history or prior (non-colonic) malignancies, provided there is no current clinical evidence of persistent or recurrent disease and the patient is on no active therapy,
    including hormonal therapy.

  • Patients may not have previously received chemotherapy for metastatic disease, except adjuvant therapy completed at least 6 months before the first evidence of metastasis.

  • Patients must have a systolic blood pressure < 150 mmHg and a diastolic pressure < 100 mmHg, (the use of antihypertensive medications to achieve these goals is allowed.)

  • Estimated life expectancy of at least 12 weeks.

ENROLLMENT TARGET: 47- *Enrollment is 36 as of 11/2013

Back to top

 

 

Back to top